Scienture (NASDAQ:SCNX – Get Free Report) posted its earnings results on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02, FiscalAI reports. The business had revenue of $0.34 million for the quarter, compared to analyst estimates of $1.96 million.
Scienture Price Performance
NASDAQ SCNX traded up $0.01 on Thursday, reaching $0.47. The company had a trading volume of 1,153,556 shares, compared to its average volume of 1,939,076. The firm has a market capitalization of $18.89 million, a PE ratio of -0.19 and a beta of 3.26. Scienture has a 1 year low of $0.24 and a 1 year high of $2.60. The firm has a 50-day moving average of $0.38 and a 200-day moving average of $0.40.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scienture in a research report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $1.50.
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in Scienture stock. Virtu Financial LLC purchased a new stake in shares of Scienture Holdings, Inc. (NASDAQ:SCNX – Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 89,930 shares of the company’s stock, valued at approximately $46,000. Virtu Financial LLC owned approximately 0.22% of Scienture at the end of the most recent quarter. 5.68% of the stock is currently owned by hedge funds and other institutional investors.
About Scienture
Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.
Read More
- Five stocks we like better than Scienture
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Scienture Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scienture and related companies with MarketBeat.com's FREE daily email newsletter.
